Triple negative breast cancers (TNBC) are a heterogenous group of diseases, defined by the absence of detectable estrogen and progesterone receptors (ESR1, PGR), non-amplified/normally expressed Her2 receptor (ERBB2), and characterized by aggressive clinical behaviour and poor prognosis. Here, PGR is linked to triple-negative breast carcinoma.